Cargando…

LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer

Long non-coding RNAs (LncRNA) as the key regulators in all stages of tumorigenesis and metastasis. However, the underlying mechanisms are largely unknown. Here, we report a lncRNA RP11-214F16.8, which renamed Lnc-PCIR, is upregulated and higher RNA level of Lnc-PCIR was positively correlated to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Wenhui, Li, Jingyi, Huang, Haobo, Fu, Fangmeng, Lin, Yuxiang, Wang, Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128249/
https://www.ncbi.nlm.nih.gov/pubmed/34012913
http://dx.doi.org/10.3389/fonc.2021.630300
_version_ 1783694083758227456
author Guo, Wenhui
Li, Jingyi
Huang, Haobo
Fu, Fangmeng
Lin, Yuxiang
Wang, Chuan
author_facet Guo, Wenhui
Li, Jingyi
Huang, Haobo
Fu, Fangmeng
Lin, Yuxiang
Wang, Chuan
author_sort Guo, Wenhui
collection PubMed
description Long non-coding RNAs (LncRNA) as the key regulators in all stages of tumorigenesis and metastasis. However, the underlying mechanisms are largely unknown. Here, we report a lncRNA RP11-214F16.8, which renamed Lnc-PCIR, is upregulated and higher RNA level of Lnc-PCIR was positively correlated to the poor survival of patients with triple negative breast cancer (TNBC) tissues. Lnc-PCIR overexpression significantly promoted cell proliferation, migration, and invasion in vitro and in vivo. RNA pulldown, RNA immunoprecipitation (RIP) and RNA transcriptome sequencing technology (RNA-seq) was performed to identify the associated proteins and related signaling pathways. Mechanistically, higher Lnc-PCIR level of blocks PABPC4 proteasome-dependent ubiquitination degradation; stable and highly expressed PABPC4 can further increase the stability of TAB3 mRNA, meanwhile, overexpression of Lnc-PCIR can disrupt the binding status of TAB3 and TAB2 which lead to activate the TNF-α/NF-κB pathway in TNBC cells. Our findings suggest that Lnc-PCIR promotes tumor growth and metastasis via up-regulating the mRNA/protein level of TAB3 and PABPC4, activating TNF-α/NF-κB signaling pathway in TNBC.
format Online
Article
Text
id pubmed-8128249
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81282492021-05-18 LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer Guo, Wenhui Li, Jingyi Huang, Haobo Fu, Fangmeng Lin, Yuxiang Wang, Chuan Front Oncol Oncology Long non-coding RNAs (LncRNA) as the key regulators in all stages of tumorigenesis and metastasis. However, the underlying mechanisms are largely unknown. Here, we report a lncRNA RP11-214F16.8, which renamed Lnc-PCIR, is upregulated and higher RNA level of Lnc-PCIR was positively correlated to the poor survival of patients with triple negative breast cancer (TNBC) tissues. Lnc-PCIR overexpression significantly promoted cell proliferation, migration, and invasion in vitro and in vivo. RNA pulldown, RNA immunoprecipitation (RIP) and RNA transcriptome sequencing technology (RNA-seq) was performed to identify the associated proteins and related signaling pathways. Mechanistically, higher Lnc-PCIR level of blocks PABPC4 proteasome-dependent ubiquitination degradation; stable and highly expressed PABPC4 can further increase the stability of TAB3 mRNA, meanwhile, overexpression of Lnc-PCIR can disrupt the binding status of TAB3 and TAB2 which lead to activate the TNF-α/NF-κB pathway in TNBC cells. Our findings suggest that Lnc-PCIR promotes tumor growth and metastasis via up-regulating the mRNA/protein level of TAB3 and PABPC4, activating TNF-α/NF-κB signaling pathway in TNBC. Frontiers Media S.A. 2021-05-03 /pmc/articles/PMC8128249/ /pubmed/34012913 http://dx.doi.org/10.3389/fonc.2021.630300 Text en Copyright © 2021 Guo, Li, Huang, Fu, Lin and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Guo, Wenhui
Li, Jingyi
Huang, Haobo
Fu, Fangmeng
Lin, Yuxiang
Wang, Chuan
LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer
title LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer
title_full LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer
title_fullStr LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer
title_full_unstemmed LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer
title_short LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer
title_sort lncrna pcir is an oncogenic driver via strengthen the binding of tab3 and pabpc4 in triple negative breast cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128249/
https://www.ncbi.nlm.nih.gov/pubmed/34012913
http://dx.doi.org/10.3389/fonc.2021.630300
work_keys_str_mv AT guowenhui lncrnapcirisanoncogenicdriverviastrengthenthebindingoftab3andpabpc4intriplenegativebreastcancer
AT lijingyi lncrnapcirisanoncogenicdriverviastrengthenthebindingoftab3andpabpc4intriplenegativebreastcancer
AT huanghaobo lncrnapcirisanoncogenicdriverviastrengthenthebindingoftab3andpabpc4intriplenegativebreastcancer
AT fufangmeng lncrnapcirisanoncogenicdriverviastrengthenthebindingoftab3andpabpc4intriplenegativebreastcancer
AT linyuxiang lncrnapcirisanoncogenicdriverviastrengthenthebindingoftab3andpabpc4intriplenegativebreastcancer
AT wangchuan lncrnapcirisanoncogenicdriverviastrengthenthebindingoftab3andpabpc4intriplenegativebreastcancer